Remarks made by the CEO of Elan today were remarkably positive regarding the company's Tysabri treatment for Multiple Sclerosis.
Tysabri represents a great advancement in MS therapies, and not to be underestimated-- a great deal of hope inherent in a new therapeutic option. We are very happy to see that it seems that Tysabri's safety review has apparently uncovered (at least to this point) nothing further of serious concern where FDA reapproval would be highly uncertain from the company's perspective.
"It's a question of when [the drug returns] and what path that takes, not a question of if," [Kelly] Martin [CEO of Elan].
"I think the demand side of the curve is a given. What I can't predict, with the risk benefit discretions and based on individual patients or doctors, is what the uptake will be versus what it was," he said.
"(But) there's no reason over time why Tysabri would not be a very substantial drug in MS."
Martin reiterated that the safety analysis into Tysabri was scheduled to conclude by late summer, and then discussions with the U.S. Food and Drug Administration (FDA) would start. Martin thought the talks would move quickly. If an FDA approval was granted, Tysabri could be on the market "the next day."
Please click "read more" for the link to some of the better articles covering today's news.
Advertisement
Selected Article Links of Interest
Elan Predicts Suspended Drug will Return
Elan boss confident MS drug will return to market
